Hims & Hers Health, Inc. $HIMS Shares Sold by Trexquant Investment LP

Key Points

• Trexquant Investment LP has significantly reduced its stake in Hims & Hers Health, selling 262,607 shares and decreasing its holdings by 54.5% in the first quarter.
• Several institutional investors have increased their positions in Hims & Hers Health, with Farallon Capital Management boosting its stake by an astonishing 64,338.5%.
• Analysts have downgraded the stock's rating, with two investment firms lowering their ratings from "buy" to "hold," while the stock has an average price target of $38.92.

Trexquant Investment LP reduced its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 54.5% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 219,000 shares of the company's stock after selling 262,607 shares during the quarter. Trexquant Investment LP owned 0.10% of Hims & Hers Health worth $6,471,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Signaturefd LLC grew its stake in shares of Hims & Hers Health by 17.7% in the 1st quarter. Signaturefd LLC now owns 2,586 shares of the company's stock valued at $76,000 after purchasing an additional 388 shares during the last quarter. GAMMA Investing LLC grew its stake in shares of Hims & Hers Health by 128.5% in the 1st quarter. GAMMA Investing LLC now owns 5,143 shares of the company's stock valued at $152,000 after purchasing an additional 2,892 shares during the last quarter. New York State Teachers Retirement System grew its stake in shares of Hims & Hers Health by 95.2% in the 1st quarter. New York State Teachers Retirement System now owns 194,795 shares of the company's stock valued at $5,756,000 after purchasing an additional 94,983 shares during the last quarter. BNP Paribas Financial Markets purchased a new position in shares of Hims & Hers Health in the 4th quarter valued at approximately $1,230,000. Finally, Fifth Third Bancorp grew its stake in shares of Hims & Hers Health by 165.4% in the 1st quarter. Fifth Third Bancorp now owns 1,542 shares of the company's stock valued at $46,000 after purchasing an additional 961 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

HIMS has been the topic of a number of analyst reports. UBS Group set a $30.00 price target on Hims & Hers Health in a research note on Monday, June 23rd. Morgan Stanley restated an "equal weight" rating and issued a $40.00 price target on shares of Hims & Hers Health in a research note on Wednesday, June 11th. Deutsche Bank Aktiengesellschaft restated a "hold" rating on shares of Hims & Hers Health in a research note on Wednesday, May 7th. Wall Street Zen downgraded Hims & Hers Health from a "buy" rating to a "hold" rating in a research note on Monday, July 28th. Finally, Piper Sandler restated a "neutral" rating and issued a $39.00 price target (up from $35.00) on shares of Hims & Hers Health in a research note on Tuesday, May 6th. Two equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Reduce" and a consensus target price of $38.92.

Insiders Place Their Bets

In related news, CFO Oluyemi Okupe sold 23,107 shares of the company's stock in a transaction on Monday, June 23rd. The stock was sold at an average price of $47.25, for a total value of $1,091,805.75. Following the completion of the transaction, the chief financial officer directly owned 63,222 shares in the company, valued at approximately $2,987,239.50. This represents a 26.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Michael Chi sold 17,102 shares of the company's stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $59.75, for a total value of $1,021,844.50. Following the completion of the transaction, the insider owned 278,654 shares of the company's stock, valued at $16,649,576.50. The trade was a 5.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 1,395,428 shares of company stock valued at $71,753,898. 17.71% of the stock is owned by company insiders.

Hims & Hers Health Price Performance

Shares of NYSE HIMS traded down $0.77 during trading on Tuesday, reaching $41.58. The company had a trading volume of 11,799,727 shares, compared to its average volume of 33,184,676. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98. The stock has a market capitalization of $9.40 billion, a PE ratio of 51.98, a price-to-earnings-growth ratio of 2.86 and a beta of 2.14. The stock has a 50-day moving average price of $49.98 and a two-hundred day moving average price of $45.60. The company has a current ratio of 4.98, a quick ratio of 4.46 and a debt-to-equity ratio of 1.72.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $0.17 earnings per share for the quarter, missing analysts' consensus estimates of $0.18 by ($0.01). The company had revenue of $544.83 million during the quarter, compared to analyst estimates of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business's revenue was up 72.6% compared to the same quarter last year. During the same period last year, the firm earned $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.